Mariano's

Mariana Oncology is a clinical-stage biotechnology company specializing in the development of next-generation radiopharmaceuticals for the treatment of difficult-to-treat cancers. The company utilizes a proprietary discovery platform to engineer macrocyclic peptide-based radioligand therapies (RLTs) that deliver potent alpha-particle radiation, such as Actinium-225, directly to tumor cells. Their lead candidate, MC-339, is an actinium-based radioligand therapy currently being investigated for the treatment of small cell lung cancer. By combining the precision of peptides with the high potency of alpha radiation, Mariana Oncology aims to provide new therapeutic options for patients with solid tumors resistant to conventional treatments. In May 2024, the company was acquired by Novartis for $1 billion upfront, integrating its innovative platform and pipeline into Novartis's leading radiopharmaceutical portfolio.